CN102727581B - A kind of pharmaceutical composition wound to repair - Google Patents
A kind of pharmaceutical composition wound to repair Download PDFInfo
- Publication number
- CN102727581B CN102727581B CN201110090878.5A CN201110090878A CN102727581B CN 102727581 B CN102727581 B CN 102727581B CN 201110090878 A CN201110090878 A CN 201110090878A CN 102727581 B CN102727581 B CN 102727581B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- wound
- repair
- oligochitosan
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition wound to repair, the active component of described pharmaceutical composition is grouped into by the one-tenth of following weight proportion: oligochitosan 2g-8g, Radix Salviae Miltiorrhizae 0.5g-2g, Radix Angelicae Sinensis 0.2g-1g, Folium Artemisiae Argyi 0.5g-1.3g.Pharmaceutical composition has carried out wound repair experiment, and result display wound surface heals, substantially without obvious cicatrix.Cell proliferation test, prove pharmaceutical composition to the propagation of cell and regeneration function good.Present inventor has performed the acute toxicity test of aforementioned pharmaceutical compositions, judge according to acute toxicity grading criteria, this test medicine can be considered nontoxic.Therefore, pharmaceutical composition of the present invention is used for the treatment of decubital ulcer, the healing of common wound, the healing of surgical wound, burn, scald.There is larger clinical value.
Description
Technical field
The present invention relates to pharmaceutical composition, be specifically related to a kind of pharmaceutical composition wound to repair.
Background technology
At present, based on the research to oligochitosan, report it and there is antibacterial, the several functions such as antitumor, Adjust-blood lipid, immunity moderation and promotion wound repair.Because oligochitosan has good affinity to cell, the indispensable composition of oligochitosan inherently in the sugar chain structure of cell membrane top layer, plays iuntercellular identification in vivo, regulation and control, communicating information, the effects such as contact inhibition.And the structure of oligochitosan and cell closely similar, and prove that oligochitosan can act directly on cell, plays the effect of well repairing damaged cell, and can recover the function of cell by experiment, promote the growth of granulation tissue, and then promote the healing of wound.
But the present inventor finds, when being used alone oligochitosan and treating wound, its effect is not very remarkable.The present invention by by Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Folium Artemisiae Argyi and oligochitosan, with certain proportion with the use of, make new drug regimen, and by cell experiment, zoopery and clinical experiment are proved, it has potent repair to wound.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, and research design, containing the pharmaceutical composition of oligochitosan, strengthens wound repair effect.
The invention provides a kind of pharmaceutical composition wound to repair.
Pharmaceutical composition of the present invention is grouped into by the one-tenth of following weight proportion:
Oligochitosan 2g-8g, Radix Salviae Miltiorrhizae extract 0.5g-2g, eumenol 0.2g-1g, Folium Artemisiae Argyi extract 0.5g-1.3g.
Pharmaceutical composition of the present invention is preferably grouped into by the one-tenth of following weight proportion:
Oligochitosan 5g, Radix Salviae Miltiorrhizae extract 1g, eumenol 0.65g, Folium Artemisiae Argyi extract 0.8g.
Pharmaceutical composition of the present invention is obtained by following method:
Get one, 200ml beaker, add 100ml except thermal source distilled water, then add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram, boil 5min, be then cooled to room temperature, removed by filtration insoluble matter, to obtain final product.
Pharmaceutical composition of the present invention can be prepared into spray or liniment.
Each component materials of pharmaceutical composition of the present invention all can commercially availablely obtain.
The present inventor has carried out wound repair experiment to aforementioned pharmaceutical compositions, and result display wound surface heals, substantially without obvious cicatrix.Cell proliferation test, prove drug regimen to the propagation of cell and regeneration function good.Present inventor has performed the acute toxicity test of aforementioned pharmaceutical compositions, show to judge according to acute toxicity grading criteria, this test medicine can be considered nontoxic.
Therefore, pharmaceutical composition of the present invention is used for the treatment of decubital ulcer, the healing of common wound, the healing of surgical wound, burn, scald.
Detailed description of the invention
Embodiment 1 pharmaceutical compositions
Each component materials of pharmaceutical composition all can commercially availablely obtain.
Oligochitosan purity > 98% degree of polymerization < 10
Radix Salviae Miltiorrhizae extract Tanshinone content > 98%
Eumenol lactone content 1%, ferulic acid 0.8%
The use part of Folium Artemisiae Argyi extract brown ceramic powder, 10: 1 plants: leaf, loss on drying < 5%, ash < 3.5%, heavy metal < 10PPM, pesticide residues < 2PPM, total amount of bacteria < 1000CFU/gm.
Get one, 200ml beaker, add 100ml except thermal source distilled water, then add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram, boil 5min, then be cooled to room temperature (25 DEG C), removed by filtration insoluble matter, obtains liniment.
The pharmaceutical composition that embodiment 1 obtains is used for following test.
Embodiment 2 acute toxicity test
Experimental animal: kunming mice 70, body weight 17-22g, male and female half and half.Purchased from Shanghai Si Kelai laboratory animal Co., Ltd.
Animal divides into groups: adopt the male and female Stochastic Equilibrium method of dividision into groups respectively, be divided into 7 groups, often organize 10, wherein one group is blank group.
Dosage is determined: metering is designed to 3ml/kg (Clinical design dosage), 10ml/kg, 50ml/kg, 100ml.
Administration: disposable gastric infusion: fasting 3-5 hour before administration, fasting 1-2 hour after administration, water is can't help in fasting.Adopt administered in portions, negative control group, first administration of 3ml/kg, 5.0ml/kg, determines after administration that set dosage is suitable, then gives 10ml/kg and 10.0ml/kg.Continuous Observation more than 7 days after administration, every day, the upper and lower noon respectively observed once subsequently, Continuous Observation 14 days.The every observation index of itemized record.
| Group | Dosage ml/kg | Quantity | Survival rate % |
| 1 | 10 | 100 | |
| 2 | 3 | 10 | 100 |
| 3 | 10 | 10 | 100 |
| 4 | 50 | 10 | 100 |
| 5 | 100 | 10 | 100 |
Conclusion: when tested material gastric infusion dosage in this test reaches 100ml/kg (being equivalent to the solid drugs of 7.45g/kg) there is not death.Judge according to acute toxicity grading criteria, this test medicine can be considered nontoxic.
Embodiment 3 wound repair is tested
Experimental animal: C57 mice, 16-18g, male, purchased from Shanghai Si Kelai laboratory animal Co., Ltd.
Test method: test mice is divided into blank group, matched group 1 (U.S. 3M medical adhesive tape), matched group 2 (Britain executes expensive precious Convatee product), matched group 3 (golden English peptide EGF), experimental group, often organizes 20.The modeling of mouse back unhairing otch, wound surface iodophor disinfection, then uses appropriate normal saline debridement, then at surface coverage matched group 1 product, matched group 2 product; Spraying matched group 3 product and experimental group medicine, natural drying, finally covers with sterile gauze.Wound recovery situation respectively with regard to 3 days, 7 days and 14 days contrasts.Result is as following table:
Embodiment 4 cell proliferation test
Cell strain: people's epidermis protein cell strain colo-16
Reagent: culture medium: DMEM, containing 10% hyclone, 100 μ g/ml penicillins, the streptomycin of 100 μ g/ml; MTT, is made into the solution of 5mg/ml concentration with the PBS of PH7.2 before using; DMSO inoculates epidermis cell: when the colo-16 Growth of Cells of cultivation is close to monolayer, draw upper feelings liquid in bottle, use 0.3% trypsinization, add appropriate DMEM and make cell monolayer suspension, be inoculated in 96 orifice plates, every hole 200 μ L puts 37 degree of 5% CO2 gas incubator and cultivates.
Drug treating: inoculate after 24 hours, draw each hole supernatant and non-attached cell, adds matched group 1 (peace skin relaxes) respectively, matched group 2 (golden English peptide EGF), after experimental group dosing, continue cultivation 3 days, observation of cell proliferative conditions under inverted microscope.
| Group | Cell proliferation OD value |
| Matched group 1 | 0.15±0.021 |
| Matched group 2 | 0.17±0.045 |
| Experimental group | 0.38±0.088 |
Result: pharmaceutical composition to the propagation of cell and regeneration function good.
Claims (4)
1. wound is had to a pharmaceutical composition for repair, it is characterized in that, described pharmaceutical composition is grouped into by the one-tenth of following weight proportion: oligochitosan 2g-8g, Radix Salviae Miltiorrhizae extract 0.5g-2g, eumenol 0.2g-1g, Folium Artemisiae Argyi extract 0.5g-1.3g.
2. wound is had to a pharmaceutical composition for repair, it is characterized in that, the active component of described pharmaceutical composition is grouped into by the one-tenth of following weight proportion: oligochitosan 5g, Radix Salviae Miltiorrhizae extract 1g, eumenol 0.65g, Folium Artemisiae Argyi extract 0.8g.
3. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition is prepared by following method:
Get one, 200ml beaker, add 100ml depyrogenation distilled water, then add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram, boil 5min, be then cooled to room temperature, removed by filtration insoluble matter, to obtain final product.
4. pharmaceutical composition according to claim 1 and 2, is characterized in that, described pharmaceutical composition is spray or liniment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110090878.5A CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110090878.5A CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102727581A CN102727581A (en) | 2012-10-17 |
| CN102727581B true CN102727581B (en) | 2016-02-10 |
Family
ID=46984345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110090878.5A Active CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727581B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421479D0 (en) * | 2014-12-03 | 2015-01-14 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| CN107773687A (en) * | 2016-08-30 | 2018-03-09 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat burn and scald |
| CN111840499B (en) * | 2019-04-01 | 2022-05-31 | 鄂州职业大学 | Warm moxibustion bag for preventing pressure sores and preparation method thereof |
| CN111729041A (en) * | 2020-07-16 | 2020-10-02 | 张勇 | A Chinese medicinal composition for treating burn and scald, and its preparation method |
-
2011
- 2011-04-11 CN CN201110090878.5A patent/CN102727581B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| "中药抗感染洗剂治疗骨外伤性创面感染57例";任敬等;《陕西中医学院学报》;20110131;第34卷(第1期);摘要，第59页左列第1.3部分和右列表1 * |
| "低分子量壳聚糖的制备及其应用研究";高维等;《武汉工业学院学报》;20070930;第26卷(第3期);第30页左列第3.2部分第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102727581A (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919961B (en) | Drug composition for treating cold and preparation method thereof | |
| CN102727581B (en) | A kind of pharmaceutical composition wound to repair | |
| CN106265822A (en) | There are anti-inflammation raw myofunctional Mahonia bealei (Fort.) Carr. extract, preparation method and applications | |
| CN102727579B (en) | A kind of pharmaceutical composition being used for the treatment of oral ulcer | |
| CN113440563B (en) | Compound houttuynia cordata spray and preparation method and application thereof | |
| Rawal Jatin et al. | Determination of bioactive components of Cynodon dactylon by GC-MS analysis & it’s in vitro antimicrobial activity | |
| CN103130865A (en) | Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| CN102526573A (en) | Medicament for treating child cold | |
| CN110946948A (en) | Application of Huafengdan in preparation of anti-breast cancer drugs | |
| CN102406858B (en) | Disinfection antibacterial agent | |
| CN110507665A (en) | Application of the glycyrrhizic acid in the drug for preparing preventing respiratory viruses infection | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations | |
| CN102727580B (en) | A kind of pharmaceutical composition foot wounds to repair | |
| CN103638052A (en) | Polyrhachis dives extractive, and preparation and medical purpose thereof | |
| CN102727578A (en) | Pharmaceutical composition for healing wounds generated by chemoradiotherapy | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| WO2006053487A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| CN109999086A (en) | Treat pig polyserositis and arthritic Chinese medicine composition and preparation method thereof | |
| CN106831386A (en) | Application of the new fern chlorins compound in treatment diabetes | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection | |
| CN101485714B (en) | Cajanus cajan leaf extract and application of monomer ingredient thereof in preparing medicament for resisting gram-positive bacteria | |
| CN105055504A (en) | Feed additive compound essential oil for preventing diarrhea of pigeons as well as preparation method and application of essential oil | |
| Archana et al. | A study of Cardiovascular and antimicrobial effects of Tinospora cordifolia | |
| CN107789393A (en) | A kind of pharmaceutical composition for treating wound caused by chemicotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |